biostudies-literaturePatutina ORussian state-funded projectRussian Science Foundation122https://www.ebi.ac.uk/biostudies/studies/S-EPMC12845401biostudies-literatureUnknown18(1)<b>Background and Objectives:</b> Aggressive cancer development is characterized by rapid tumor growth and progressive immune dysfunction. Tumor-derived microRNAs (miRNAs) emerge as master regulators of both malignant transformation and immune evasion, making them promising therapeutic targets. Using the highly aggressive CT-26 peritoneal adenomatosis model, this study explored the potential of selective miRNA inhibition to simultaneously suppress tumor growth and overcome immunosuppression. <b>Methods and Results:</b> Our results revealed that inhibition of miR-155, miR-21, and miR-17 by methylsulfonyl phosphoramidate (mesyl) oligonucleotides exhibited markedly different therapeutic profiles. miR-155 inhibition demonstrated minimal efficacy. miR-21 suppression provided early tumor regressPharmaceuticsTargeted Inhibition of Oncogenic microRNAs miR-21, miR-17, and miR-155 Suppresses Tumor Growth and Modulates Immune Response in Colorectal Cancer.PMC1284540119-74-30011125012300659-6Awad MZenkova MGladkikh DSavin IZhukov SMiroshnichenko SKupryushkin MMarkov OSen'kova AVlassov VPatutina OSeroklinova EMaslov MfalseTargeted Inhibition of Oncogenic microRNAs miR-21, miR-17, and miR-155 Suppresses Tumor Growth and Modulates Immune Response in Colorectal Cancer.<b>Background and Objectives:</b> Aggressive cancer development is characterized by rapid tumor growth and progressive immune dysfunction. Tumor-derived microRNAs (miRNAs) emerge as master regulators of both malignant transformation and immune evasion, making them promising therapeutic targets. Using the highly aggressive CT-26 peritoneal adenomatosis model, this study explored the potential of selective miRNA inhibition to simultaneously suppress tumor growth and overcome immunosuppression. <b>Methods and Results:</b> Our results revealed that inhibition of miR-155, miR-21, and miR-17 by methylsulfonyl phosphoramidate (mesyl) oligonucleotides exhibited markedly different therapeutic profiles. miR-155 inhibition demonstrated minimal efficacy. miR-21 suppression provided early tumor regress2026-01-01T00:00:00Z2026 Jan2026-06-16T03:11:27.313Z2026-06-16T03:07:11.164ZS-EPMC128454014159922910.3390/pharmaceutics18010122